[lufkindailynews.com] It’s an alternative choice than to get the watchman implant. [www.fda.gov] [abbott.mediaroom.com] The below says following the implant, no NOAC is needed because it’s dual-seal technology. No post implant TEEs? Repositionable? #1 implant in Europe? “The approval of Abbott's Amulet device provides physicians with a treatment option that reduces the risk of stroke and eliminates the need for blood-thinning medication immediately after the procedure, which is incredibly valuable given the bleeding risks associated with these medicines." Before this approval, the only minimally invasive option for LAA occlusion for U.S. physicians and their patients was a solution with a single component to seal the LAA that requires blood-thinning drugs to heal and additional patient monitoring to ensure closure. In contrast, Abbott's Amulet uses dual-seal technology to completely and immediately seal the LAA. Amulet recipients do not need to use blood-thinning medication following the procedure. Additionally, the device can treat a broad range of anatomies and has the widest range of occluder sizes on the market; it is also recapturable and repositionable to ensure optimal placement. "Amulet's unique dual-seal approach has made it the number one LAA closure product in Europe, so today's device approval by the FDA is an important milestone in allowing us to bring this treatment option to American physicians and patients," said Michael Dale, senior vice president of Abbott's structural heart business. "Consistent with our mission purpose, our minimally invasive Amulet procedure for reducing stroke risk in patients with atrial fibrillation will help people live better lives through better health." [www.ahajournals.org] More complications for a lesser experienced EP. https://www.afibbers.org/forum/read.php?9,185518,185518#msg-185518 Sat, 24 Oct 2026 23:09:57 +0000 Phorum 5.2.23 https://www.afibbers.org/forum/read.php?9,185518,185524#msg-185524 https://www.afibbers.org/forum/read.php?9,185518,185524#msg-185524 [www.dicardiology.com]

“ The study showed that the two devices achieve a similar rate of LAA occlusion at 45 days, but through different mechanisms. The Amulet also was associated with higher procedural complications, but similar clinical outcomes at 45-days.”

If it has higher procedural complications, why chose it over the watchman? My speculation is the immediate discontinuation of a NOAC due to its double sealing technology.]]> susan.d AFIBBERS FORUM Mon, 23 May 2022 00:25:56 +0000 https://www.afibbers.org/forum/read.php?9,185518,185521#msg-185521 https://www.afibbers.org/forum/read.php?9,185518,185521#msg-185521 www.afibbers.org]]]> GeorgeN AFIBBERS FORUM Sun, 22 May 2022 17:48:55 +0000 https://www.afibbers.org/forum/read.php?9,185518,185518#msg-185518 https://www.afibbers.org/forum/read.php?9,185518,185518#msg-185518 lufkindailynews.com]
It’s an alternative choice than to get the watchman implant.

[www.fda.gov]

[abbott.mediaroom.com]
The below says following the implant, no NOAC is needed because it’s dual-seal technology. No post implant TEEs? Repositionable? #1 implant in Europe?

“The approval of Abbott's Amulet device provides physicians with a treatment option that reduces the risk of stroke and eliminates the need for blood-thinning medication immediately after the procedure, which is incredibly valuable given the bleeding risks associated with these medicines."

Before this approval, the only minimally invasive option for LAA occlusion for U.S. physicians and their patients was a solution with a single component to seal the LAA that requires blood-thinning drugs to heal and additional patient monitoring to ensure closure. In contrast, Abbott's Amulet uses dual-seal technology to completely and immediately seal the LAA. Amulet recipients do not need to use blood-thinning medication following the procedure. Additionally, the device can treat a broad range of anatomies and has the widest range of occluder sizes on the market; it is also recapturable and repositionable to ensure optimal placement.

"Amulet's unique dual-seal approach has made it the number one LAA closure product in Europe, so today's device approval by the FDA is an important milestone in allowing us to bring this treatment option to American physicians and patients," said Michael Dale, senior vice president of Abbott's structural heart business. "Consistent with our mission purpose, our minimally invasive Amulet procedure for reducing stroke risk in patients with atrial fibrillation will help people live better lives through better health."

[www.ahajournals.org]
More complications for a lesser experienced EP.]]> susan.d AFIBBERS FORUM Sun, 22 May 2022 07:03:56 +0000